NCT02993146
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 1
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with diffuse leptomeningeal & pachymeningeal carcinomatosis; Patients who have received prior whole brain radiation therapy- see trial for details
https://ClinicalTrials.gov/show/NCT02993146